Covid-19 roundup: Pfizer/BioNTech say booster is 95.6% effective; European Parliament calls for more vaccine transparency
A month after the FDA authorized a booster dose of Pfizer and BioNTech’s Covid-19 shot for certain at-risk individuals, the companies are releasing new data that suggest the extra shot has a 95.6% efficacy compared to the two-dose series.
The results come from a Phase III trial that tested a third 30 µg dose of the vaccine given at a median of 11 months, compared to a placebo on top of Pfizer’s two-dose series. A thousand participants 16 years and older participated, just over 23% of whom were 65 or older.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.